Baudax Bio, Inc.
BXRXQ · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $5 |
| Gross Profit | $0 | $0 | $0 | -$4 |
| % Margin | – | – | – | -1,445.8% |
| R&D Expenses | $2 | $2 | $3 | $1 |
| G&A Expenses | $4 | $2 | $0 | $0 |
| SG&A Expenses | $4 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$4 | $3 | $0 | $1 |
| Operating Expenses | $2 | $7 | $5 | $4 |
| Operating Income | -$2 | -$7 | -$5 | -$9 |
| % Margin | – | – | – | -2,773.9% |
| Other Income/Exp. Net | -$0 | -$0 | -$3 | -$1 |
| Pre-Tax Income | -$2 | -$7 | -$7 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$7 | $11 | -$9 |
| % Margin | – | – | – | -2,983.9% |
| EPS | -0.3 | -1.51 | 4.91 | -12.33 |
| % Growth | 80.1% | -130.8% | 139.8% | – |
| EPS Diluted | -0.3 | -1.51 | 4.91 | -12.33 |
| Weighted Avg Shares Out | 8 | 5 | 2 | 1 |
| Weighted Avg Shares Out Dil | 8 | 5 | 2 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$4 | -$5 | -$8 |
| % Margin | – | – | – | -2,442.3% |